Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Neuroendocrine 1

Interventions

Cyclophosphamide 3167 Cisplatin 3163 Carboplatin 2940 Paclitaxel 2675 Radiotherapy 2648 Gemcitabine 2548 pembrolizumab 2334 Docetaxel 2158 Bevacizumab 2129 Fluorouracil 1822 Capecitabine 1785 Oxaliplatin 1713 Dexamethasone 1591 Nivolumab 1517 Doxorubicin 1479 Rituximab 1455 Etoposide 1342 Magnetic Resonance Spectroscopy 1270 Irinotecan 1235 Leucovorin 1217 Cytarabine 1124 Pemetrexed 1064 Drug Therapy 1062 fludarabine 1052 Vincristine 958 Specimen Handling 940 Prednisone 927 Cetuximab 921 Lenalidomide 917 Trastuzumab 903

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × DLL3 protein, human × Clear all

NCT06893783 2026-04-13

DeLLight

Asan Medical Center

Phase 2 Recruiting

Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon ⚡